 |
市場調查報告書
商品編碼
2075354
反義寡核苷酸市場：依產品類型、應用、治療應用和地區分類Antisense Oligonucleotides Market, By Product Type, By Application, By Therapeutic Use, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，反義寡核苷酸市場規模將達到 24.8 億美元，到 2033 年將達到 60.5 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 13.6%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 24.8億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 13.60% | 2033年市場規模預測： | 60.5億美元 |
全球反義寡核苷酸市場涵蓋多種產品類型，包括修飾型反義寡核苷酸、未修飾型反義寡核苷酸和間隙寡核苷酸，並應用於腫瘤學、神經系統疾病和感染疾病等領域。市場需求主要受罕見遺傳疾病和慢性病治療領域應用日益廣泛以及對更有效率、更可靠解決方案的需求不斷成長的推動。持續的技術進步和終端用戶需求的不斷提高是推動該市場成長的主要動力。
市場動態：
腫瘤學和神經病學領域應用範圍的擴大、終端用戶需求的成長以及對提高效率和性能的持續關注，預計將是推動全球反義寡核苷酸市場成長的主要因素。更廣泛的選擇也使得這些解決方案能夠惠及更廣泛的使用者群體。
例如，各公司正在拓展產品系列，以滿足罕見遺傳疾病和慢性病領域不斷變化的需求。此外，預計在預測期內，加大創新投入和整合新技術將為市場參與者創造新的成長機會。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，介紹了全球反義寡核苷酸市場主要公司的概況。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
- 這份全球反義寡核苷酸市場報告的目標受群眾外包括產業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用全球反義寡核苷酸市場分析中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場概覽
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
- 夥伴關係方案
- 品牌和定價分析
- 銷售代理情況
- 波特的分析
- 技術進步
- 主要進展
- 市場趨勢
- 前景
- 按銷售收入排名的主要公司
第4章 反義寡核苷酸市場：依產品類型分類，2026-2033年
- 修飾的反義寡核苷酸
- 未修飾的反義寡核苷酸
- Gapmixer
- Mixmers
- 其他
第5章 反義寡核苷酸市場：依應用領域分類，2026-2033年
- 腫瘤學
- 神經病變
- 感染疾病
- 心血管疾病
- 其他
第6章 反義寡核苷酸市場：依治療類型分類，2026-2033年
- 罕見遺傳疾病
- 慢性病
- 感染疾病
- 藥物輸送系統
- 其他
第7章 反義寡核苷酸市場：依地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
- 亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
- 中東和非洲
- 巴林
- 科威特
- 阿曼
- 卡達
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 北非
- 中非
- 其他中東國家
第1章 競爭情勢
- Ionis Pharmaceuticals
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Biogen
- Pfizer
- Novartis
- Akcea Therapeutics
- Wave Life Sciences
- Dyne Therapeutics
- ProQR Therapeutics
第2章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI1879
Antisense Oligonucleotides Market is estimated to be valued at USD 2.48 billion in 2026 and is expected to reach USD 6.05 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.48 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.60% | 2033 Value Projection: | USD 6.05 billion |
The global antisense oligonucleotides market covers a broad set of product type categories, including Modified Antisense Oligonucleotides, Unmodified Antisense Oligonucleotides, and Gapmers, used across applications such as Oncology, Neurological Disorders, and Infectious Diseases. Demand is supported by adoption among Rare Genetic Disorders, and Chronic Diseases and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.
Market Dynamics:
Growing adoption across Oncology, and Neurological Disorders, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global antisense oligonucleotides market. A wider range of available options is making these solutions accessible to a broader base of users.
For instance, companies are expanding their portfolios to address evolving requirements across Rare Genetic Disorders, and Chronic Diseases. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global antisense oligonucleotides market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Ionis Pharmaceuticals, Sarepta Therapeutics, Alnylam Pharmaceuticals, Biogen, Pfizer, Novartis, Akcea Therapeutics, Wave Life Sciences, Dyne Therapeutics, and ProQR Therapeutics, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global antisense oligonucleotides market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antisense oligonucleotides market.
Detailed Segmentation:
- Global Antisense Oligonucleotides Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
- Modified Antisense Oligonucleotides
- Unmodified Antisense Oligonucleotides
- Gapmers
- Mixmers
- Others
- Global Antisense Oligonucleotides Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Oncology
- Neurological Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Others
- Global Antisense Oligonucleotides Market, By Therapeutic Use (Revenue, USD Bn, 2021 - 2033)
- Rare Genetic Disorders
- Chronic Diseases
- Infectious Diseases
- Drug Delivery Systems
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Ionis Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Biogen
- Pfizer
- Novartis
- Akcea Therapeutics
- Wave Life Sciences
- Dyne Therapeutics
- ProQR Therapeutics
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By Therapeutic Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Antisense Oligonucleotides Market By Product Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Modified Antisense Oligonucleotides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Unmodified Antisense Oligonucleotides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Gapmixer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Mixmers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Antisense Oligonucleotides Market By Application, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Antisense Oligonucleotides Market By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Rare Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Chronic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Drug Delivery Systems
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Antisense Oligonucleotides Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Akcea Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Wave Life Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dyne Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ProQR Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
